Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-01

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the adjunctive effects of systemic antibiotics used in nonsurgical periodontal treatment (NSPT), compared with NSPT alone, on the periodontal clinical parameters and resistin level in diabetic patients with periodontitis, in order to identify which, one provides an additional effect to non-surgical periodontal therapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus

NCT02845024

Diabetes Mellitus With Periodontal Disease

COMPLETED NA

Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics

NCT01595594

Periodontal Disease Type 2 Diabetes

COMPLETED PHASE3

Efficacy of Subgingivally Delivered Doxycycline Plus Ketoprofen Gel as an Adjunct to Non-surgical Periodontal Treatment

NCT02538224

Chronic Periodontitis

COMPLETED PHASE2/PHASE3

The Effects of Periodontal Therapy on Glycemic Control in Diabetic Patients

NCT03783845

Chronic Periodontitis, Generalized

COMPLETED PHASE4

Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy

NCT03343366

Chronic Periodontitis Type 2 Diabetes Mellitus

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Diseases Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

Chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

Group Type ACTIVE_COMPARATOR

Group I

Intervention Type DRUG

First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

Group II

Received azithromycin dosage is 250 mg/day for 5 days, after an initial dose of 500 mg one hour before NSPT

Group Type EXPERIMENTAL

Group II

Intervention Type DRUG

Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.

Group III

Consisted of 5 type 2 Diabetes Mellitus patients with periodontitis who were received doxycycline 20mg twice/day.

Group Type EXPERIMENTAL

Group III

Intervention Type DRUG

Third group are Type 2 DM patients who received doxycycline 20mg twice/day.

Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group I

First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

Intervention Type DRUG

Group II

Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.

Intervention Type DRUG

Group III

Third group are Type 2 DM patients who received doxycycline 20mg twice/day.

Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients were clinically diagnosed as having at least three site with CAL ≥ 5mm; moderate to advanced chronic periodontitis according to the criteria of American Academy of Periodontology.

* Free from any other systemic conditions that affect the periodontium except for Diabetes mellitus type II.
* No periodontal therapy, systemic antibiotics or non-steroidal anti-inflammatory agents during the preceding 6 months.
* Non-smokers.
* Non-pregnant.